Interleukin 2 News and Research

RSS

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

Interleukin Genetics, Inc. announced today financial and operational results for the first quarter ended March 31, 2010.

14 May 2010

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

Probiotics are a group of live microorganisms administered in adequate amounts which confer a beneficial health effect on the host. This bacterial community plays a pivotal role in human nutrition and health by promoting the supply of nutrients, preventing pathogen colonization and shaping and maintaining normal mucosal immunity.

13 May 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.

7 May 2010

PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis

PurGenesis Technologies Inc. announced today positive results from a Phase I clinical trial on PUR0110, the Company's lead investigational new drug for the treatment of ulcerative colitis. This successful trial was designed to evaluate the safety and maximum tolerated dose of PUR0110.

6 May 2010

New data on Surfaxin LS presented at 2010 PAS Annual Meeting

Discovery Laboratories, Inc., announced that new data regarding Surfaxin LS (its novel, lyophilized KL4 surfactant dosage form) were presented at the 2010 Pediatric Academic Societies Annual Meeting. The two studies presented demonstrate that Surfaxin LS improves lung function and oxygenation while attenuating lung inflammation in the preterm lamb model of respiratory distress syndrome.

5 May 2010

Immune system responds aggressively when looking at sick people

Just seeing someone who looks sick is enough to make your immune system work harder, according to a new study in which volunteers looked at pictures of sick people. This may help fight off pathogens, says Mark Schaller from the University of British Columbia who conducted the research. "It seems like it's probably good for the immune system to be responding especially aggressively at times when it looks like you are likely to be coming into contact with something that might make you sick."

4 May 2010

EpiCept's first Ceplene commercial shipment to the EU triggers $2M milestone payment from Meda

EpiCept Corporation today announced that it has earned a $2 million milestone payment from Meda AB, for the first commercial shipment of Ceplene® (histamine dihydrochloride) to a major country in the European Union, as defined in the agreement.

4 May 2010

Majority of patients who appear healthy may be at risk for cardiovascular disease

Three separate studies announced today at the American Society of Hypertension Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010) examined the cardiovascular consequences of relatively healthy patients - those who were asymptomatic and not classified as hypertensive or diabetic - and found that many patients who appear healthy may still be at risk for cardiovascular disease.

3 May 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, announced the successful conclusion of the Company's second Phase I/II clinical trial of the Multimeric-001 Universal Influenza Vaccine.

28 Apr 2010

Study links progression of lethal type of brain tumor with reduced expression of immune system genes

A new study links progression of a lethal type of brain tumor with reduced expression of more than 600 immune system genes, suggesting how complex the immune response is to the cancer and the resulting difficulty in targeting specific immune system proteins for treatment.

27 Apr 2010

Exercise helps retain greater bone density: Researchers

The stage for osteoporosis is set well before menopause-but exercise can help rewrite the script, according to Medical College of Georgia researchers.

26 Apr 2010

Chokeberry extract reduces weight gain in insulin-resistant animals

Chokeberry bushes have for centuries been residents of eastern deciduous forests where their bright red and dark purple fruits continue to be favorite snacks of local bird species. Native Americans have also traditionally eaten dried chokeberries and prepared teas from parts of the plant, and several domesticated varieties now grace contemporary lawns and gardens from coast to coast.

26 Apr 2010

Controlling actions of FSH may help treat osteoporosis in menopausal women

Diminished bone density is common among menopausal women and raises their risk of osteoporosis, bone fractures and subsequent complications. Research has traditionally focused on therapies that seek to maintain the level of estrogen in the body. This hormone seems to sustain bone health, but it drops to an extremely low level during and after menopause.

26 Apr 2010

GBS serotype III more commonly associated with urinary tract infections

Research suggests pathogenic strains of Group B Streptococcus (GBS) are an under-recognised cause of urinary tract infections.

24 Apr 2010

LFA felicitates Yale University professor on receipt of US DoD's PRMRP research grant

The Lupus Foundation of America, Inc. (LFA) congratulates Insoo Kang, M.D., Associate Professor of Medicine, Yale University for being selected to receive a $1.2 million research grant from the U.S. Department of Defense's (DoD) Congressionally Directed Peer Reviewed Medical Research Program (PRMRP). The DoD award will fund a three-year study that will investigate whether and why lupus patients make more of the chemical interleukin (IL-27), which causes decreased generation of T cells and is known to play an important role in autoimmunity and lupus.

24 Apr 2010

Transposagen Biopharmaceuticals announces new TGEM Rat Model product line

Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today that it has added 170 genetically modified rats and related biomaterials to its database of laboratory rats with a genetic modification that can mimic a human disease. These animals are used by academic, pharmaceutical, and biotech scientists for drug discovery and development research and will be sold under Transposagen's new TGEM(TM) Rat Models brand.

23 Apr 2010

Severe and necrotizing AP characterized by depletion of circulating lymphocytes

Mortality of patients with severe acute pancreatitis (SAP) approaches 30%-40%. An imbalance between the early systemic inflammatory response syndrome (SIRS), and the later compensatory counter-inflammatory response, and development of multiple organ failure (MOF) are considered to be the primary causes of morbidity and mortality in SAP. Excessive leukocyte activation (including neutrophils and monocyte-macrophage lineage) with cytokinemia play a critical role in the pathogenesis of pancreatitis and even more so, of the subsequent inflammatory response.

20 Apr 2010

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that independent researchers presented results showing that XOMA's antibody to interleukin-1 beta (IL-1 beta), XOMA 052, was highly effective in reducing production of a protein that supports the proliferation of cancerous human myeloma cells in vitro.

20 Apr 2010

EpiCept announces U.K. launch of Ceplene

EpiCept Corporation today announced that the commercial launch of Ceplene® (histamine dihydrochloride) will take place in the United Kingdom on April 20, 2010 in conjunction with the British Society for Haematology 50th Annual Scientific Meeting in Edinburgh, Scotland. Ceplene is approved in the European Union for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission.

20 Apr 2010

Interleukin 2 News and Research

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis

New data on Surfaxin LS presented at 2010 PAS Annual Meeting

Immune system responds aggressively when looking at sick people

EpiCept's first Ceplene commercial shipment to the EU triggers $2M milestone payment from Meda

Majority of patients who appear healthy may be at risk for cardiovascular disease

REGN reports net loss of $30.5M for first-quarter 2010

BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine

Study links progression of lethal type of brain tumor with reduced expression of immune system genes

Exercise helps retain greater bone density: Researchers

Chokeberry extract reduces weight gain in insulin-resistant animals

Controlling actions of FSH may help treat osteoporosis in menopausal women

GBS serotype III more commonly associated with urinary tract infections

LFA felicitates Yale University professor on receipt of US DoD's PRMRP research grant

Transposagen Biopharmaceuticals announces new TGEM Rat Model product line

Severe and necrotizing AP characterized by depletion of circulating lymphocytes

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

EpiCept announces U.K. launch of Ceplene

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News